Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women’s Health
Hologic, Inc. (Nasdaq: HOLX), a global women's health champion, has announced a definitive agreement to acquire Gynesonics, Inc., a private medical device company, for approximately $350 million. Gynesonics develops the Sonata® System, a minimally invasive technology for diagnosing and treating symptomatic uterine fibroids, including those causing heavy menstrual bleeding. The system combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.
Brandon Schnittker, Division President of Surgical Solutions at Hologic, stated that the acquisition will expand options for GYN surgeons globally to treat women with heavy periods and fibroids. The deal aligns with Hologic's commitment to providing minimally invasive treatment options and enhancing women's quality of life. The acquisition's completion is subject to customary closing conditions and regulatory approvals.
Hologic, Inc. (Nasdaq: HOLX), un leader globale nella salute delle donne, ha annunciato un accordo definitivo per acquisire Gynesonics, Inc., un'azienda privata di dispositivi medici, per circa 350 milioni di dollari. Gynesonics sviluppa il Sonata® System, una tecnologia minimamente invasiva per diagnosticare e trattare i fibromi uterini sintomatici, compresi quelli che causano forti sanguinamenti mestruali. Il sistema combina l'ecografia intrauterina in tempo reale con l'ablazione a radiofrequenza mirata in una procedura senza incisioni.
Brandon Schnittker, Presidente della Divisione Soluzioni Chirurgiche di Hologic, ha dichiarato che l'acquisizione espanderà le opzioni per i chirurghi GYN a livello globale per trattare le donne con mestruazioni abbondanti e fibromi. L'accordo è in linea con l'impegno di Hologic nel fornire opzioni di trattamento minimamente invasive e nel migliorare la qualità della vita delle donne. Il completamento dell'acquisizione è soggetto a condizioni di chiusura consuete e approvazioni regolatorie.
Hologic, Inc. (Nasdaq: HOLX), un campeón global de la salud de la mujer, ha anunciado un acuerdo definitivo para adquirir Gynesonics, Inc., una empresa privada de dispositivos médicos, por aproximadamente 350 millones de dólares. Gynesonics desarrolla el Sonata® System, una tecnología mínimamente invasiva para diagnosticar y tratar fibromas uterinos sintomáticos, incluidos los que causan sangrado menstrual abundante. El sistema combina ultrasonido intrauterino en tiempo real con ablación por radiofrecuencia dirigida en un procedimiento sin incisiones.
Brandon Schnittker, presidente de la División de Soluciones Quirúrgicas de Hologic, afirmó que la adquisición ampliará las opciones para los cirujanos GYN a nivel mundial para tratar a las mujeres con períodos abundantes y fibromas. El acuerdo está alineado con el compromiso de Hologic de proporcionar opciones de tratamiento mínimamente invasivas y mejorar la calidad de vida de las mujeres. La finalización de la adquisición está sujeta a las condiciones habituales de cierre y aprobaciones regulatorias.
Hologic, Inc. (Nasdaq: HOLX)는 여성 건강 분야의 글로벌 리더로서, 개인 의료 기기 회사인 Gynesonics, Inc.를 약 3억 5천만 달러에 인수하기 위한 최종 계약을 발표했습니다. Gynesonics는 Sonata® System을 개발하고 있으며, 이는 증상 있는 자궁 섬유종 진단 및 치료를 위한 최소 침습 기술로, 많은 월경 출혈을 유발하는 섬유종도 포함됩니다. 이 시스템은 실시간 자궁 내 초음파 유도와 목표화된 라디오 주파수 절제술을 결합하여 절개 없는 절차를 제공합니다.
브랜든 슈니트커 Hologic 외과 솔루션 부문 사장은 이 인수가 전 세계 GYN 외과 의사들이 많은 월경을 겪는 여성과 섬유종을 치료할 수 있는 옵션을 확장할 것이라고 밝혔습니다. 이 거래는 최소 침습 치료 옵션 제공 및 여성의 삶의 질 향상에 대한 Hologic의 약속과 일치합니다. 인수 완료는 통상적인 마감 조건과 규제 승인을 받아야 합니다.
Hologic, Inc. (Nasdaq: HOLX), un champion mondial de la santé des femmes, a annoncé un accord définitif pour acquérir Gynesonics, Inc., une entreprise médicale privée, pour environ 350 millions de dollars. Gynesonics développe le Sonata® System, une technologie peu invasive pour diagnostiquer et traiter des fibromes utérins symptomatiques, y compris ceux provoquant des saignements menstruels abondants. Le système combine un guidage échographique intra-utérin en temps réel avec une ablation par radiofréquence ciblée dans une procédure sans incision.
Brandon Schnittker, Président de la Division des Solutions Chirurgicales chez Hologic, a déclaré que l'acquisition élargira les options pour les chirurgiens GYN du monde entier afin de traiter les femmes ayant des menstruations abondantes et des fibromes. L'accord s'inscrit dans l'engagement de Hologic à fournir des options de traitement peu invasives et à améliorer la qualité de vie des femmes. L'achèvement de l'acquisition est soumis aux conditions de clôture habituelles et aux approbations réglementaires.
Hologic, Inc. (Nasdaq: HOLX), ein globaler Champion der Frauengesundheit, hat einen endgültigen Vertrag über die Übernahme von Gynesonics, Inc., einem privaten Medizintechnikunternehmen, für etwa 350 Millionen Dollar bekannt gegeben. Gynesonics entwickelt das Sonata® System, eine minimal-invasive Technologie zur Diagnose und Behandlung von symptomatischen Gebärmuttermyomen, einschließlich solcher, die starke Menstruationsblutungen verursachen. Das System kombiniert die Echtzeit-Uterus-Ultraschallführung mit gezielter Radiofrequenzablation in einem schnittfreien Verfahren.
Brandon Schnittker, Präsident der Geschäftseinheit Surgical Solutions bei Hologic, erklärte, dass die Übernahme die Optionen für GYN-Chirurgen weltweit erweitern wird, um Frauen mit starken Perioden und Myomen zu behandeln. Das Geschäft steht im Einklang mit Hologics Engagement, minimal invasive Behandlungsoptionen anzubieten und die Lebensqualität von Frauen zu verbessern. Der Abschluss der Übernahme unterliegt den üblichen Abschlussbedingungen und regulatorischen Genehmigungen.
- Acquisition of Gynesonics for $350 million expands Hologic's women's health portfolio
- Addition of Sonata® System provides minimally invasive treatment for uterine fibroids
- Strengthens Hologic's position in the global GYN surgical market
- Aligns with company strategy to enhance women's quality of life through innovative treatments
- Significant cash outlay of $350 million for the acquisition
- Potential integration challenges and costs associated with merging Gynesonics' operations
- Regulatory approval required, which could delay or potentially hinder the acquisition
Insights
Hologic's acquisition of Gynesonics for
Financially, while the
This move could potentially drive long-term growth for Hologic by expanding its addressable market and diversifying its product offerings. However, the success will hinge on effective integration and market adoption of the Sonata System.
The acquisition of Gynesonics represents a significant advancement in Hologic's women's health portfolio. The Sonata System's incisionless procedure for treating uterine fibroids is a game-changer in gynecological care. This technology addresses a critical need, as uterine fibroids affect up to
The combination of real-time intrauterine ultrasound guidance with targeted radiofrequency ablation offers a less invasive alternative to traditional surgical options like hysterectomy or myomectomy. This could lead to faster recovery times, reduced complications and improved quality of life for patients.
From a research perspective, this acquisition could accelerate innovation in minimally invasive gynecological procedures. It will be important to monitor long-term clinical outcomes and compare the Sonata System's efficacy to existing treatments to fully understand its impact on patient care.
Gynesonics, which is based in
“Gynesonics’ Sonata System complements our offering and will give GYN surgeons across the globe an expanded range of options to treat women suffering from heavy periods and fibroids,” said Brandon Schnittker, Division President of Surgical Solutions at Hologic. “This acquisition furthers our commitment to providing women with minimally invasive treatment options. We are enthusiastic about the future as we work to expand access to and drive innovation for treatments that enhance women’s quality of life.”
Completion of the acquisition is subject to customary closing conditions, including receipt of required regulatory approvals.
About Hologic, Inc.
Hologic, Inc. is a global champion of women’s health, focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com.
About Gynesonics
Gynesonics pioneered and launched the Sonata System, the first FDA-cleared medical device for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids. The Sonata System is an incisionless solution, clinically proven to reduce fibroid symptoms. For more information, go to www.gynesonics.com.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic and Gynesonics products and Hologic and Gynesonics plans, objectives, expectations and intentions. Such statements include, but are not limited to, financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; each company’s strategies, positioning, resources, capabilities, and expectations for future performance; and each company’s outlook and financial and other guidance. There can be no assurance the Hologic or Gynesonics products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis, or that the products will be commercially successful or achieve any expected level of sales. These forward-looking statements are based upon assumptions made as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
Risks and uncertainties that could adversely affect either Hologic’s or Gynesonics’ business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the risk that conditions to closing the proposed acquisition will not be satisfied; the possibility that the anticipated benefits from the proposed transaction or products cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Gynesonics operations with those of Hologic will be greater than expected; the ability of Hologic and Gynesonics to retain and hire key personnel; the coverage and reimbursement decisions of third-party payers and the guidelines, recommendations, and studies published by various organizations relating to the use of products and treatments; the ability to successfully manage ongoing organizational and strategic changes, including Hologic’s ability to attract, motivate and retain key employees; the development of new competitive technologies and products; regulatory approvals and clearances for products or the proposed transaction; the anticipated development of markets in which products are sold into and the success of products in these markets; the anticipated performance and benefits of products; estimated asset and liability values; anticipated trends relating to Hologic’s financial condition or results of operations; and Hologic’s capital resources and the adequacy thereof; and other factors described in Hologic’s filings with the SEC. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in
Source: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014079208/en/
Media Contact
Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com
Investor Contact
Ryan Simon
Vice President, Investor Relations
(+1) 858.410.8514
ryan.simon@hologic.com
Source: Hologic, Inc.
FAQ
What is the value of Hologic's acquisition of Gynesonics?
What is the Sonata® System developed by Gynesonics?
How does the Gynesonics acquisition align with Hologic's business strategy?
What conditions need to be met for Hologic's acquisition of Gynesonics to be completed?
